Moderna, Inc. has increased its market value by roughly $28 billion in the past week. This surge suggests investors' expectations extend beyond the potential of melanoma treatment.
| Checkpoint | Current state | Why it matters |
|---|---|---|
| Full Phase 3 data | Topline only | Tests the size and durability of benefit |
| Regulatory path | Discussions planned | Sets filing timing and evidence burden |
| Other tumors | Eight-trial program | Needed to support platform valuation |
| Manufacturing | Individualized | Determines speed, scale and margins |
The scientific milestone is real. The commercial case is still preliminary.
Record Amtagvi sales and a 56% gross margin powered the rerating. The shares now sit near their 52-week high and almost level with the broader analyst target.
Market data: August 19, 2026 close, 16:00 EDT
Prepared after the U.S. session
Highest close in about three years
Phase 3 melanoma readout
One session, Financial Times estimate
Close × 399.24M shares
Investor read: the market priced a platform, not just a melanoma product. The $44 billion value gain equals about 14.7× Barclays’ $3 billion estimate for 2035 melanoma sales.
INTerpath-001 enrolled 1,137 patients with resected stage IIB-IV melanoma. No new safety signal was reported.
| Firm | View | Target |
|---|---|---|
| Piper Sandler | Overweight | $77 |
| Goldman Sachs | Neutral | $67 |
| Citigroup | Neutral | $60 |
| RBC Capital | Sector Perform | $45 |
| Wolfe Research | Underperform | $25 |
The $174.38 close is 126% above the old high target and 243% above the $50.84 consensus. These targets have not absorbed the trial result.
Bars share a $44 billion scale. The sales figure is an analyst estimate for melanoma in 2035, not company guidance.
| Next U.S. session | August 20, 09:30 EDT |
| Analyst model resets | Watch targets and probability assumptions |
| Medical presentation | Date not yet disclosed |
| Regulatory path | Companies are already in discussions |
| Possible availability | 2027, subject to approval |
| Metric | Value |
|---|---|
| Q2 revenue | $145M |
| Q2 GAAP net loss | $(782)M |
| June 30 cash & investments | $6.9B |
| July settlement payment | $(950)M |
| 2026 year-end cash guide | $4.7–5.2B |
